106 related articles for article (PubMed ID: 35245914)
1. Triple Threat: Response to the Crises of COVID-19, Homelessness, and Opioid Use Disorder With a Novel Approach to Buprenorphine Delivery: A Case Series.
Samuel L; Caygill-Walsh R; Suen LW; Mohebbi S; Geier M
J Addict Med; 2022 Nov-Dec 01; 16(6):733-735. PubMed ID: 35245914
[TBL] [Abstract][Full Text] [Related]
2. Mobile, Community-Based Buprenorphine Treatment for Veterans Experiencing Homelessness With Opioid Use Disorder: A Pilot, Feasibility Study.
Iheanacho T; Payne K; Tsai J
Am J Addict; 2020 Nov; 29(6):485-491. PubMed ID: 32367557
[TBL] [Abstract][Full Text] [Related]
3. Association of Shelter-in-Place Hotels With Health Services Use Among People Experiencing Homelessness During the COVID-19 Pandemic.
Fleming MD; Evans JL; Graham-Squire D; Cawley C; Kanzaria HK; Kushel MB; Raven MC
JAMA Netw Open; 2022 Jul; 5(7):e2223891. PubMed ID: 35895061
[TBL] [Abstract][Full Text] [Related]
4. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.
Carter J; Zevin B; Lum PJ
Addict Sci Clin Pract; 2019 May; 14(1):20. PubMed ID: 31060600
[TBL] [Abstract][Full Text] [Related]
5. Care and Complexity in Emergency Housing: an Examination of the COVID-19 Shelter-in-Place (SIP) Hotel Program to House People Experiencing Homelessness in San Francisco.
Abbs E; Schoenfeld N; Lai M; Satterwhite S; Zhou S; Bamberger J; Zevin B
J Urban Health; 2023 Apr; 100(2):303-313. PubMed ID: 36652157
[TBL] [Abstract][Full Text] [Related]
6. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
[TBL] [Abstract][Full Text] [Related]
7. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
8. Assessment of a Hotel-Based COVID-19 Isolation and Quarantine Strategy for Persons Experiencing Homelessness.
Fuchs JD; Carter HC; Evans J; Graham-Squire D; Imbert E; Bloome J; Fann C; Skotnes T; Sears J; Pfeifer-Rosenblum R; Moughamian A; Eveland J; Reed A; Borne D; Lee M; Rosenthal M; Jain V; Bobba N; Kushel M; Kanzaria HK
JAMA Netw Open; 2021 Mar; 4(3):e210490. PubMed ID: 33651111
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series.
Peckham AM; Kehoe LG; Gray JR; Wakeman SE
J Subst Abuse Treat; 2021 Jul; 126():108316. PubMed ID: 34116808
[TBL] [Abstract][Full Text] [Related]
10. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.
Lucas GM; Chaudhry A; Hsu J; Woodson T; Lau B; Olsen Y; Keruly JC; Fiellin DA; Finkelstein R; Barditch-Crovo P; Cook K; Moore RD
Ann Intern Med; 2010 Jun; 152(11):704-11. PubMed ID: 20513828
[TBL] [Abstract][Full Text] [Related]
11. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H
Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302
[TBL] [Abstract][Full Text] [Related]
13. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
[TBL] [Abstract][Full Text] [Related]
14. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
16. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
Worley MJ; Heinzerling KG; Shoptaw S; Ling W
Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
[TBL] [Abstract][Full Text] [Related]
17. Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits, and healthcare cost compared to late initiation.
Sun T; Aroke H; Kogut S; Katenka N; Bratberg J; Buchanan A
Am J Drug Alcohol Abuse; 2022 Mar; 48(2):217-225. PubMed ID: 34780312
[No Abstract] [Full Text] [Related]
18. Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine.
Stein MD; VanNoppen D; Herman DS; Anderson BJ; Conti M; Bailey GL
J Subst Abuse Treat; 2022 May; 136():108661. PubMed ID: 34801283
[TBL] [Abstract][Full Text] [Related]
19. Extended-release buprenorphine outcomes among treatment resistant veterans.
Cotton AJ; Lo K; Kurtz FB; Waldbauer L
Am J Drug Alcohol Abuse; 2022 May; 48(3):334-337. PubMed ID: 34780319
[No Abstract] [Full Text] [Related]
20. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
[No Abstract] [Full Text] [Related]
[Next] [New Search]